Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAL-MI: Dutogliptin + Filgrastim in STEMI
NCT05881382Phase 3Not yet recruiting
- Sponsor
- Recardio Inc.
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing Dutogliptin + Filgrastim with Placebo (2 arms). Primary endpoint: Time to first occurrence of cardiovascular death or worsening heart failure at 180 days. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
dutogliptin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05881382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881382.